NCT06295731Phase 2, phase 3Active not recruiting

INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

Study sponsor: Inhibrx Biosciences, Inc · INBX

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2029-05Estimated

Enrollment · participants410Estimated

Source updated2026-05-08Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-03-31 · 1 field changed

Recruitment status changed

− Before

~~Recruiting~~

+ After

Active not recruiting

Check registry source

Study details

Conditions studied

Head and Neck Squamous Cell Carcinoma (HNSCC)

Treatments or interventions studied

INBRX-106DrugAlso known as Hexavalent OX40 agonist antibody
PembrolizumabDrugAlso known as Keytruda

Primary outcomes · main study measures

Read the study measures

measure: Phase 2: Objective Response Rate (ORR); description: ORR is defined as the proportion of patients with a complete response (CR) or partial response (PR) on 2 consecutive occasions ≥4 weeks apart, per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1); timeFrame: up to 6 months; measure: Phase 3: Progression-Free Survival (PFS); description: PFS is defined as the time from randomization to first occurrence of PD, as determined by the Investigator according to RECIST v 1.1, or death from any cause (whichever occurs first).; timeFrame: From randomization to first occurrence of progressive disease (PD) or death (up to 4 years); measure: Phase 3: Overall Survival (OS); description: OS is the time from randomization to death due to any cause; timeFrame: From randomization until death from any cause (up to 4 years)

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history